Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study.

CONTEXT A small subset of patients with depression exhibit new or worsening suicidal thoughts or behavior during short-term treatment with antidepressants. Because cyclic adenosine monophosphate response element binding (CREB) protein has been implicated in both antidepressant mechanisms and suicide, the CREB1 gene represents a gene that possibly influences the risk for treatment-emergent suicidality. OBJECTIVE To examine polymorphisms that span CREB1, which was previously associated with anger expression in men with major depressive disorder, for association with new or worsening suicidality. DESIGN Nested case-control study derived from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, a multicenter, prospective, open, 12-week effectiveness trial from July 1, 2001, to September 30, 2006. SETTING Outpatient primary care and psychiatric clinics. Patients Individuals with nonpsychotic major depressive disorder for whom DNA was available and who did not report suicidal ideation at study entry were subsequently treated with citalopram hydrobromide for up to 12 weeks. MAIN OUTCOME MEASURE Emergent suicidal ideation, defined as a score of 2 or higher on any postbaseline visit for participants whose baseline score was 0 or 1 on the 16-item Quick Inventory of Depressive Symptomatology-Clinician Rated suicide item. RESULTS Of 1447 participants, 124 (8.6%) subsequently reported suicidality on at least 1 visit; these individuals were compared with the remaining 1324 participants. Of 5 single nucleotide polymorphisms (SNPs) examined, none were significantly associated with treatment-emergent suicidality overall. However, 2 SNPs revealed a gene-by-sex interaction with suicidality. Among the 539 men, these 2 SNPs and 2 of the 5 SNP haplotypes were significantly associated with new-onset suicidality. CONCLUSIONS Polymorphisms that span CREB1 were associated with treatment-emergent suicidality among men with depression, extending an observation of association with male anger expression in a prior independent cohort. If replicated, this finding would suggest that pharmacogenetic testing could facilitate the identification of the small subset of individuals at greater risk during short-term antidepressant treatment.

[1]  M. Fava,et al.  Clinical and Genetic Dissection of Anger Expression and CREB1 Polymorphisms in Major Depressive Disorder , 2007, Biological Psychiatry.

[2]  J. Amsterdam,et al.  Treatment-Associated Suicidal Ideation and Adverse Effects in an Open, Multicenter Trial of Fluoxetine for Major Depressive Episodes , 2006, Psychotherapy and Psychosomatics.

[3]  Francis J McMahon,et al.  Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. , 2006, American journal of human genetics.

[4]  H. Cordell.  Estimation and testing of genotype and haplotype effects in case‐control studies: comparison of weighted regression and multiple imputation procedures , 2006, Genetic epidemiology.

[5]  M. Fava,et al.  An Evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: A Sequenced Treatment Alternatives to Relieve Depression Trial Report , 2006, Biological Psychiatry.

[6]  J. Kennedy,et al.  The interaction between TPH2 promoter haplotypes and clinical–demographic risk factors in suicide victims with major psychoses , 2005, Genes, brain, and behavior.

[7]  S. Gabriel,et al.  Efficiency and power in genetic association studies , 2005, Nature Genetics.

[8]  E. Klein,et al.  Alterations in cell adhesion molecule L1 and functionally related genes in major depression: A postmortem study , 2005, Biological Psychiatry.

[9]  J. Škavić,et al.  Variability of the tryptophan hydroxylase gene: Study in victims of violent suicide , 2005, Psychiatry Research.

[10]  M. Fava,et al.  Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. , 2005, The Journal of clinical psychiatry.

[11]  D. Brent,et al.  Family genetic studies, suicide, and suicidal behavior , 2005, American journal of medical genetics. Part C, Seminars in medical genetics.

[12]  P. Duberstein,et al.  The association of irritability and impulsivity with suicidal ideation among 15- to 20-year-old males. , 2004, Suicide & life-threatening behavior.

[13]  H. Möller,et al.  Single nucleotide polymorphism and haplotype analysis of a novel tryptophan hydroxylase Isoform (TPH2) gene in suicide victims , 2004, Biological Psychiatry.

[14]  B. Maher,et al.  Genome‐wide linkage survey for genetic loci that affect the risk of suicide attempts in families with recurrent, early‐onset, major depression , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[15]  H. Jick,et al.  Antidepressants and the risk of suicidal behaviors. , 2004, JAMA.

[16]  B. Bondy,et al.  Serotonin 1B (5HT‐1B) receptor polymorphism (G861C) in suicide victims: Association studies in German and Slavic population , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[17]  G. Tsai,et al.  Association between serotonin transporter gene promoter polymorphism and suicide: results of a meta-analysis , 2004, Biological Psychiatry.

[18]  G. MacQueen,et al.  Amygdala cyclic adenosine monophosphate response element binding protein phosphorylation in patients with mood disorders: effects of diagnosis, suicide, and drug treatment , 2004, Biological Psychiatry.

[19]  Y. Zhu,et al.  Cholecystokinin-B receptor gene expression in cerebellum, pre-frontal cortex and cingulate gyrus and its association with suicide , 2004, Neuroscience Letters.

[20]  P. Sham,et al.  Haplotype Association Analysis of Discrete and Continuous Traits Using Mixture of Regression Models , 2004, Behavior genetics.

[21]  D. Kupfer,et al.  Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. , 2004, Controlled clinical trials.

[22]  M H Trivedi,et al.  The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation , 2004, Psychological Medicine.

[23]  B. Maher,et al.  Genome‐wide linkage survey for genetic loci that influence the development of depressive disorders in families with recurrent, early‐onset, major depression , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[24]  Gustavo Turecki,et al.  Impaired Repression at a 5-Hydroxytryptamine 1A Receptor Gene Polymorphism Associated with Major Depression and Suicide , 2003, The Journal of Neuroscience.

[25]  J. Markowitz,et al.  The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression , 2003, Biological Psychiatry.

[26]  C. Benkelfat,et al.  A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: II. Suicidal behavior , 2003, Molecular Psychiatry.

[27]  D. Kupfer,et al.  Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. , 2003, The Psychiatric clinics of North America.

[28]  Maurizio Fava,et al.  Diagnosis and definition of treatment-resistant depression , 2003, Biological Psychiatry.

[29]  W. Brown,et al.  Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. , 2003, The American journal of psychiatry.

[30]  Yogesh K. Dwivedi,et al.  Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide subjects. , 2003, Archives of general psychiatry.

[31]  L. Cardon,et al.  Population stratification and spurious allelic association , 2003, The Lancet.

[32]  G. Fava.  Can long-term treatment with antidepressant drugs worsen the course of depression? , 2003, The Journal of clinical psychiatry.

[33]  B. Maher,et al.  Genetic linkage of region containing the CREB1 gene to depressive disorders in women from families with recurrent, early-onset, major depression. , 2002, American journal of medical genetics.

[34]  J. Aldenhoff,et al.  Changes in CREB-phosphorylation during recovery from major depression. , 2002, Journal of psychiatric research.

[35]  M. Palkovits,et al.  High activity-related allele of MAO-A gene associated with depressed suicide in males , 2002, Neuroreport.

[36]  M. Detke,et al.  Duloxetine in the treatment of depression: A double-blind placebo-controlled comparison with paroxetine , 2002, European Neuropsychopharmacology.

[37]  E. Tan,et al.  No evidence for association of the T102C polymorphism in the serotonin type 2A receptor with suicidal behavior in schizophrenia. , 2002, American journal of medical genetics.

[38]  K. Bucholz,et al.  A twin study of genetic and environmental influences on suicidality in men , 2002, Psychological Medicine.

[39]  B. Gutiérrez,et al.  The 5-HT(2A) receptor gene 102T/C polymorphism is associated with suicidal behavior in depressed patients. , 2001, American journal of medical genetics.

[40]  K. Bucholz,et al.  Suicide attempts in an adolescent female twin sample. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[41]  R. Shelton,et al.  Cross-talk between PKA and PKC in human fibroblasts: what are the pharmacotherapeutic implications? , 2001, Journal of affective disorders.

[42]  W. van den Brink,et al.  Suicide risk in placebo-controlled studies of major depression. , 2001, The American journal of psychiatry.

[43]  M. Leboyer,et al.  Suicide attempts and the tryptophan hydroxylase gene , 2001, Molecular Psychiatry.

[44]  J. Guimón,et al.  Cyclic AMP-mediated signaling components are upregulated in the prefrontal cortex of depressed suicide victims , 2001, Brain Research.

[45]  R. Strausberg,et al.  High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[46]  P. Zwanzger,et al.  Lack of association of serotonin-2A receptor gene polymorphism (T102C) with suicidal ideation and suicide. , 2000, American journal of medical genetics.

[47]  Thomas J. Carmody,et al.  The Inventory of Depressive Symptomatology (IDS): Clinician (IDS‐C) and Self‐Report (IDS‐SR) ratings of depressive symptoms , 2000 .

[48]  R A Steer,et al.  Risk factors for suicide in psychiatric outpatients: a 20-year prospective study. , 2000, Journal of consulting and clinical psychology.

[49]  A. Ravindran,et al.  Association of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorder. , 2000, American journal of medical genetics.

[50]  G. Engström,et al.  Temperament traits in seasonal affective disorder, suicide attempters with non-seasonal major depression and healthy controls. , 1999, Journal of affective disorders.

[51]  C Waternaux,et al.  Toward a clinical model of suicidal behavior in psychiatric patients. , 1999, The American journal of psychiatry.

[52]  G. MacQueen,et al.  Increased temporal cortex CREB concentrations and antidepressant treatment in major depression , 1998, The Lancet.

[53]  Gerald L. Brown,et al.  A tryptophan hydroxylase gene marker for suicidality and alcoholism. , 1998, Archives of general psychiatry.

[54]  L. Bierut,et al.  Suicidal behaviour: an epidemiological and genetic study , 1998, Psychological Medicine.

[55]  A. Beck,et al.  Psychometric characteristics of the Scale for Suicide Ideation with psychiatric outpatients. , 1997, Behaviour research and therapy.

[56]  A. Rush,et al.  The Inventory of Depressive Symptomatology (IDS): psychometric properties , 1996, Psychological Medicine.

[57]  R W Makuch,et al.  Can treatment that is helpful on average be harmful to some patients? A study of the conflicting information needs of clinical inquiry and drug regulation. , 1996, Journal of clinical epidemiology.

[58]  Susan A. Nolan,et al.  Gender Differences in Hostility Among Depressed and Medical Outpatients , 1995, The Journal of nervous and mental disease.

[59]  J. Kaprio,et al.  Self‐reported hostility and suicidal acts, accidents, and accidental deaths: a prospective study of 21,443 adults aged 25 to 59. , 1994, Psychosomatic medicine.

[60]  S. Marder,et al.  Fluoxetine, akathisia, and suicidality: is there a causal connection? , 1992, Archives of general psychiatry.

[61]  A. Rothschild,et al.  Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. , 1991, The Journal of clinical psychiatry.

[62]  C. Beasley,et al.  Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. , 1991, BMJ.

[63]  W. Reynolds.  Psychometric characteristics of the Adult Suicidal Ideation Questionnaire in college students. , 1991, Journal of personality assessment.

[64]  M. Riddle,et al.  Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. , 1991, Journal of the American Academy of Child and Adolescent Psychiatry.

[65]  P. Masand,et al.  Suicidal ideation related to fluoxetine treatment. , 1991, The New England journal of medicine.

[66]  Martin H. Teicher,et al.  Emergence of intense suicidal preoccupation during fluoxetine treatment. , 1990, The American journal of psychiatry.

[67]  P. Vitaliano,et al.  Anger, hostility, and depression in assaultive vs. suicide-attempting males. , 1989, Journal of clinical psychology.

[68]  J. Ferguson,et al.  Paradoxical worsening of depressive symptomatology caused by antidepressants. , 1988, Journal of clinical psychopharmacology.

[69]  T. Crook,et al.  Factors associated with attempted suicide among hospitalized depressed patients , 1975, Psychological Medicine.

[70]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[71]  J. Savarino,et al.  Suicide risk during antidepressant treatment. , 2006, The American journal of psychiatry.

[72]  B. Lebowitz,et al.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. , 2006, The American journal of psychiatry.

[73]  B. Maher,et al.  Sequence variations in CREB1 cosegregate with depressive disorders in women , 2003, Molecular Psychiatry.

[74]  山田 真吾.  Reduced phosphorylation of cyclic AMP-responsive element binding protein in the postmortem orbitofrontal cortex of patients with major depressive disorder , 2003 .

[75]  S. Gabriel,et al.  Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus , 2002, Molecular Psychiatry.

[76]  J. Samet,et al.  Food and Drug Administration , 2007, BMJ : British Medical Journal.

[77]  J. Overholser,et al.  Assessment of mode of anger expression in adolescent psychiatric inpatients. , 2001, Adolescence.